The director of the Joseph Epstein Center for Emergency Medicine Research discussed the complexities of diagnosing migraine in the emergency department and whether institutions should reevaluate their internal processes to do so. [WATCH TIME: 3 minutes]
The director of the epilepsy center at Cleveland Clinic Neurological Institute spoke on one of the studies he coauthored that were presented at AES 2021. [WATCH TIME: 4 minutes]
The advantages of using the pyrimidine synthesis inhibitor teriflunomide to treat relapsing-remitting multiple sclerosis.
Considerations that affect which S1P receptor modulator may be used to treat relapsing-remitting multiple sclerosis, and how to best utilize them during COVID-19.
The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed the need for specificity and artificial intelligence for patients with epilepsy. [WATCH TIME: 4 minutes]
The director of the Joseph Epstein Center for Emergency Medicine Research discussed the origin behind her multinational study evaluating the outcome of headache in emergency departments. [WATCH TIME: 3 minutes]
The CEO of ZZ Biotech outlined the design of the phase 2 trial of 3KA-APC, which will enroll 16 patients with amyotrophic lateral sclerosis. [WATCH TIME: 4 minutes]
Elizabeth Thiele, MD, PhD, and Elaine C. Wirrell, MD, explain how community neurologists can work with academic center to treat patients with Dravet or Lennox-Gastaut syndromes.
Two experts list new therapies being developed for the treatment of Dravet and Lennox-Gastaut syndromes.
Drs Thiele and Wirrell discuss the benefits of 3 drugs being approved to treat Dravet and Lennox-Gastaut syndromes: cannabidiol, fenfluramine, and the combination of stiripentol and clobazam.
The director of the Tuberous Sclerosis Clinic at Cincinnati Children’s discussed the phase 2 open-label study of ganaxolone in TSC and whether drug development remains the top priority for these patients. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending December 11, 2021. [WATCH TIME: 4 minutes]
The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute spoke on the latest advances with epilepsy surgery, as well as what still needs to be learned. [WATCH TIME: 5 minutes]
An introduction to the use of novel agents for preventive migraine therapy.
An expert panel discusses migraine prevention with the use of behavioral therapies such as cognitive behavioral therapy and stress management.
The director of Cleveland Clinic’s Epilepsy Center at the Cleveland Clinic Neurological Institute discussed poignant presentations from the 2021 American Epilepsy Society Annual Meeting. [WATCH TIME: 7 minutes]
The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed numerous presentations from AES 2021 that bolstered cenobamate’s known efficacy and safety profile. [WATCH TIME: 7 minutes]
The scientific director at the Dravet Syndrome Foundation commented on the concern associated with vaccination in this patient population, noting that investigators have not observed an exacerbated risk profile with the COVID-19 vaccines. [WATCH TIME: 2 minutes]
Dr David Kudrow shares some advice for community neurologists on the acute and preventive treatment of migraine.
The scientific director at the Dravet Syndrome Foundation discussed a recent survey asking caregivers about the experiences of patients with DS following COVID-19 vaccination. [WATCH TIME: 3 minutes]
What to know about using S1P receptor modulators as oral therapy for relapsing-remitting multiple sclerosis.
Experts discuss types of oral fumarates that are available to treat relapsing-remitting multiple sclerosis, and best practices for selecting an option based on trial data and clinical experience.
The clinical psychologist at Cleveland Clinic discussed the potential of using cognitive behavioral therapy for treatment of psychogenic non-epileptic seizures on cognitive behavioral therapy. [WATCH TIME: 3 minutes]
Neurology News Network for the week ending December 4, 2021. [WATCH TIME: 4 minutes]
Two experts explain the impact of the drug fenfluramine’s FDA approval in the treatment of Dravet syndrome.
Drs Thiele and Wirrell continue analyzing the benefits of cannabidiol as a therapeutic option for patients with Dravet or Lennox-Gastaut syndromes.
A key opinion leader illustrates how recently approved rimegepant for preventive episodic migraine treatment could change the treatment landscape.
David Kudrow, MD, reviews the available FDA-approved injectable CGRP antagonists for preventive migraine treatment.
The director of the Chambers-Grundy Center for Transformative Neuroscience at the University of Nevada–Las Vegas discussed the positive trends within the Alzheimer drug development space. [WATCH TIME: 2 minutes]
